3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
1889
Carcinoma, Non-Small-Cell Lung
1350
Prostatic Neoplasms
980
Colorectal Neoplasms
851
Multiple Myeloma
741
Leukemia, Myeloid, Acute
725
Neoplasms
691
Lung Neoplasms
680
Neoplasm Metastasis
642
Lymphoma
579
Carcinoma, Hepatocellular
571
Pancreatic Neoplasms
567
Stomach Neoplasms
523
Leukemia
511
Recurrence
493
Leukemia, Lymphocytic, Chronic, B-Cell
459
Precursor Cell Lymphoblastic Leukemia-Lymphoma
452
Melanoma
451
Lymphoma, Non-Hodgkin
443
Ovarian Neoplasms
426
Lymphoma, Large B-Cell, Diffuse
423
Squamous Cell Carcinoma of Head and Neck
416
Myelodysplastic Syndromes
416
Head and Neck Neoplasms
404
Brain Neoplasms
403
Rectal Neoplasms
397
Glioblastoma
375
Carcinoma, Renal Cell
350
Hodgkin Disease
338
Esophageal Neoplasms
337
Interventions
dalotuzumab
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
OTHER
×
Insulin-Like Growth Factor I, Resistance To
×
Clear all
NCT00799240
2014-11-07
IMPACT
University of Kansas Medical Center
Phase 2
Completed
27 enrolled